medwireNews: A post-hoc analysis of the EMPA-REG OUTCOME trial shows the first benefits of empagliflozin appearing within the third week of taking the sodium-glucose cotransporter 2 inhibitor.
The earliest benefit appeared at day 17, when the reduction in heart failure hospitalization first achieved statistical significance, at a 90% reduction in risk for people with type 2 diabetes assigned to take empagliflozin rather than placebo.
The positive effect of empagliflozin on cardiovascular death took longer to appear, achieving a significant 72% reduction by day 59, which stabilized to a 40% reduction by day 317. The risk reduction for the combined outcome was significant by day 27.
“Taken together, these findings demonstrate the rapidity of benefit of empagliflozin in reducing the risk of cardiovascular and heart failure outcomes in this trial,” said Subodh Verma (University of Toronto, Ontario, Canada), who presented the results at the virtual ADA 80th Scientific Sessions.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group